Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/
Tweet Content
Long term safety data for bimekizumab (IL17i) in Psa & axSpA
Overall as expected; increased infections (esp fungal/candida) & hepatic events
No new signals... uveitis flares is interesting
Need H2H of IL17's! IXE vs SEC vs BIM
@RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA
Show on Archive Page
On
Display in Search Results
On
PDQ
Off